PAI-1 Study in Thalassemia Major Patients Receiving Multiple Blood Transfusion

Area of Science:

• Hematology
• Molecular Biology
• Cardiovascular Medicine

Background:

• Thalassemia is a congenital hemolytic anemia requiring frequent blood transfusions.
• Chronic iron overload and procoagulant status are significant complications in thalassemia patients.
• Procoagulant status contributes to thrombotic events in individuals with thalassemia.

Purpose of the Study:

• To investigate the procoagulant status in thalassemia major patients.
• To evaluate Plasminogen Activator Inhibitor-1 (PAI-1) as a marker for hypercoagulability in thalassemia.
• To assess the correlation between PAI-1 levels and the cumulative number of blood transfusions.

Main Methods:

• A case-control study involving 30 thalassemia major patients on regular blood transfusions and 30 healthy controls.
• Measurement of serum PAI-1 levels in both groups.
• Statistical analysis to compare PAI-1 levels between cases and controls and to assess correlations.

Main Results:

• Thalassemia major patients exhibited significantly higher mean PAI-1 levels (3683 ± 358 pg/ml) compared to healthy controls (3047 ± 414 pg/ml) (p < 0.05).
• PAI-1 levels showed a positive correlation with the total number of blood transfusions received by the patients.
• These findings indicate an increased procoagulant state in thalassemia major.

Conclusions:

• Elevated PAI-1 levels in thalassemia major patients suggest a hypercoagulable state.
• PAI-1 may serve as a valuable biomarker for assessing thrombotic risk in transfusion-dependent thalassemia.
• Further research is warranted to explore the clinical implications of PAI-1 levels in managing thalassemia complications.